Page 12 - Expanded Access News Today

“Common sense is not a gift. It's a punishment because you have to deal with everyone who doesn't have it.” This is a tough market, and common sense usually isn’t enough to get through it. Lenders have expressed the need for advice on how to stop the bleeding by employing effective revenue tactics and optimizing efficiencies in their back-office operations. Identifying key areas in which to focus via informed benchmark data is a critical component to designin...

SHELTON, CT / ACCESSWIRE / August 9, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines

Press release content from Business Wire. The AP news staff was not involved in its creation.

Cyclo Therapeutics, Inc. CYTH ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing me

WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defensin-mimetic

SHELTON, CT / ACCESSWIRE / August 4, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines

Jynneos is a live, nonreplicating, smallpox and monkeypox vaccine; ACAM2000 is a live smallpox (vaccinia) vaccine.

Tpoxx was FDA-approved in 2018 as the first drug to treat smallpox, a virus in the same family as monkeypox.

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022....

Q2 2022 total revenues were $64.4 millionTotal revenues in the first six months of 2022 were $124.6 millionVanda provides update on pipeline advan...